Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-04-15
2010-11-23
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S577000, C514S859000, C424S401000
Reexamination Certificate
active
07838558
ABSTRACT:
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
REFERENCES:
patent: 4717720 (1988-01-01), Shroot et al.
patent: 5098895 (1992-03-01), Shroot et al.
patent: 5212303 (1993-05-01), Shroot et al.
patent: RE34440 (1993-11-01), Shroot et al.
patent: 5306486 (1994-04-01), McCook et al.
patent: 5603940 (1997-02-01), Candau et al.
patent: 5665364 (1997-09-01), McAtee et al.
patent: 6383505 (2002-05-01), Kaiser et al.
patent: 6413536 (2002-07-01), Gibson et al.
patent: 7083799 (2006-08-01), Giacomoni
patent: 7579377 (2009-08-01), Graeber et al.
patent: 7642288 (2010-01-01), Graeber
patent: 2003/0157138 (2003-08-01), Eini et al.
patent: 2005/0059740 (2005-03-01), Graeber et al.
patent: 0 199 636 (1986-10-01), None
patent: 0 487 973 (1996-03-01), None
patent: 0 487 973 (1996-03-01), None
patent: 2 730 930 (1996-08-01), None
patent: WO 01/28552 (2001-04-01), None
patent: WO 02/083086 (2002-10-01), None
patent: WO 03/075908 (2003-09-01), None
Differin Gel Data Sheet (Differin Gel Data Sheet, available as of Nov. 1998, pp. 1-5.
“Topical Formulary for Carbopol® Polymers”, Noveon, Inc., The Specialty Chemicals Innovator, Pharmaceutical Polymers, pp. 1-25, Jan. 2002, Cleveland, Ohio.
Body Cream, Phytosan™, Formula No. 416.09.0077.
Jamoulle et al., “Follicular Penetration and Distribution of Topically Applied CD 271, a new Naphthoic Acid Derivative Intended for Topical Acne Treatment”,Journal of Investigative Dermatology, (1990), 94(5), 731-732, published by Nature Publishing Group.
Allec et al., “Skin distribution and pharmaceutical aspects of adapalene gel,”J. Am. Acad. Dermatol. (1997) 36:S119-S125, published by American Academy of Dermatology, Inc., US.
Shroot et al., “A New Concept of Drug Delivery for Acne”,Dermatology(1998), 196:165-170, published by S. Karger AG, Switzerland.
Rolland et al., “Site-specific Drug Delivery to Pilosebaceous Structures Using Polymeric Microspheres”,Pharmaceutical Research(1993), vol. 10, No. 12, 1738-1744, published by Plenum Publishing Corporation.
Alirezai et al., “Etude Comparative de l'efficacité et de la tolérance de gels d'adapalène à 0,1 et 0,03 p 100 et d'un gel de trétimoïne á 0,025 p 100 dans le traitement de l'acné” (Effićacy and safety comparison study of 0.1 p. 100 and 0.03 p 100 adapalene gels and tretinoin gel in the topical treatment of acne),Ann. Dermatol. Venereol. (1996), 123:165-170, published by Paris Masson, Paris, France.
Healy et al. “Acnevulgaris”,British Medical Journal, 1994 vol. 308, Iss. 6932, pp. 2-9.
Czernielewski et al. “Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne”,Journal of European Academy of Dermatology and Venerology, Dec. 2001, vol. 15, Supplement 3, pp. 5-12.
International Search Report for corresponding PCT/EP03/03246 (WO 03/075908 A1) in English.
Protest Under 37 C.F.R. § 1.291 regarding U.S. Appl. No. 11/494,693 (US 2007/0043119) with attachments dated Jun. 14, 2008.
Notification of Non-entry of Protest.
European Search Report for corresponding EP 05 003144 (in English).
Minutes for Oral Proceedings for European Application EP 03712109 corresponding to parent U.S. Appl. No. 10/937,612.
Goldfarb et al. “Photographic assessment of the effects of adapalene 0.1% and 0.3% gels and vehicle in photodamaged skin,” Abstract published in European Academy of Dermatology and Venereology JEADV (2000) 14 (Suppl. 1), 315, Wiley-Blackwell, Hoboken, New Jersey.
Kang et al. “Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial,” J. Am. Acad.Dermatol., Jul. 2003, pp. 83-90, American Academy of Dermatology, Inc., Schaumberg, Illinois.
Talukdar et al.,Journal of Pharmaceutical Sciences, May 1996, vol. 85, No. 5, 537-540.
Seppicontrol A5, Aug. 2001, pp. 1-53.
File History of U.S.P. 5,098,895 Shroot et al.
File History of Reissue 34,440, Shroot et al.
Notification of Non-Entry of Protest, dated Aug. 29, 2008 in U.S. Appl. No. 11/494,693, filed Jul. 28, 2006.
Czernielewski Janusz
Graeber Michael
Buchanan & Ingersoll & Rooney PC
Galderma Research & Development S.N.C.
Jean-Louis Samira
Padmanabhan Sreeni
LandOfFree
Administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183874